(Q42940923)

English

Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib

scientific article published on August 2010

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

11 November 2017

Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib (English)

1 reference

stated in

Europe PubMed Central

11 November 2017

1 reference

Lisa Hutchinson

1

1 reference

stated in

Europe PubMed Central

PubMed ID

20700898

retrieved

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

stated in

Europe PubMed Central

11 November 2017

Nature Reviews Clinical Oncology

1 reference

stated in

Europe PubMed Central

11 November 2017

7

1 reference

stated in

Europe PubMed Central

11 November 2017

8

1 reference

stated in

Europe PubMed Central

11 November 2017

424

1 reference

stated in

Europe PubMed Central

11 November 2017

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.113

retrieved

31 March 2020

Identifiers

DOI

10.1038/NRCLINONC.2010.113

1 reference

stated in

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

PubMed ID

20700898

retrieved

11 November 2017

(Q42940923)

Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)